Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse

Garcia, Christine; Lefkowits, Carolyn; Pelkofski, E.; Blackhall, Leslie; Duska, Linda R.

doi:10.1016/j.ygyno.2017.08.008

Cited by 17 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The grey literature search did not yield any results that met our study eligibility criteria. We contacted authors of 13 studies 53 – 59 , 68 – 73 and received responses from six authors, 54 , 55 , 69 – 72 who provided additional data for four studies. 54 , 55 , 69 , 72 …”

Section: Resultsmentioning

confidence: 99%

“…We identified two types of tools used to assess for problematic opioid use in palliative care: questionnaires ( n = 32, 76%) 53 – 55 , 57 , 58 , 61 – 63 , 65 , 66 , 68 – 89 and urine drug tests ( n = 21, 50%), 17 , 53 , 55 , 56 , 57 , 59 , 60 , 63 , 64 , 67 , 68 , 70 , 71 , 81 , 82 , 85 , 89 – 93 with an overlap of both types in 11 studies (26%). 53 , 55 , 57 , 63 ,…”

Section: Resultsmentioning

confidence: 99%

“…68 , 88 The primary study objective of 22 studies (52%) was to evaluate the use of one or more assessment tools in palliative care. 53 – 63 , 66 , 68 – 73 , 82 , 85 , 91 , 93 In the remaining studies, the primary objectives were to describe patients with problematic opioid use who were receiving palliative care ( n = 17, 40%); 60 , 64 , 67 , 74 – 81 , 84 , 86 – 88 , 90 , 92 and to evaluate the impact of interventions related to problematic opioid use in palliative care ( n = 3, 7%) 17 , 83 , 89 ( Table 2 ). Though evaluation of the tools was not the primary objective in these studies, they reported on use of these tools to assess for problematic opioid use.…”

Section: Resultsmentioning

confidence: 99%

“…The following questionnaires were used in the studies included in our review: Cut down, Annoyed, Guilty, and Eye-opener (CAGE, n = 8, 25%), 70 , 74 – 80 CAGE-Adapted to Include Drugs (CAGE-AID; n = 6, 28%), 62 , 69 , 81 – 83 , 89 Opioid Risk Tool (ORT) ( n = 9, 28%), 53 , 54 , 57 , 58 , 61 , 71 – 73 , 85 Screener and Opioid Assessment for Patients with Pain (SOAPP) ( n = 3, 9%), 65 , 66 , 69 SOAPP-Revised (SOAPP-R; n = 2, 6%), 55 , 87 and SOAPP-Short Form (SOAPP-SF; n = 5, 16%) 54 , 63 , 70 , 75 , 86 Four studies (13%) used two different questionnaires; 54 , 69 , 70 , 75 one study (3%) used a self-designed opioid dependence assessment; 88 one study (3%) used a 5-point Likert scale to measure opioid craving; 84 and one study (3%) did not specify the questionnaire that they used. 68 Supplemental Appendix D 3 provides information about the development and validation studies for CAGE, CAGE-AID, ORT, SOAPP, SOAPP-SF, and SOAPP-R questionnaires.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Assessment tools for problematic opioid use in palliative care: A scoping review

et al. 2021

View full text Add to dashboard Cite

Background: Screening for problematic opioid use is increasingly recommended in patients receiving palliative care. Aim: To identify tools used to assess for the presence or risk of problematic opioid use in palliative care. Design: Scoping review. Data sources: Bibliographic databases (inception to January 31, 2020), reference lists, and grey literature were searched to find primary studies reporting on adults receiving palliative care and prescription opioids to manage symptoms from advanced cancer, neurodegenerative diseases, or end-stage organ diseases; and included tools to assess for problematic opioid use. There were no restrictions based on study design, location, or language. Results: We identified 42 observational studies (total 14,431 participants) published between 2009 and 2020 that used questionnaires ( n = 32) and urine drug tests ( n = 21) to assess for problematic opioid use in palliative care, primarily in US ( n = 38) and outpatient palliative care settings ( n = 36). The questionnaires were Cut down, Annoyed, Guilty, and Eye-opener (CAGE, n = 8), CAGE-Adapted to Include Drugs (CAGE-AID, n = 6), Opioid Risk Tool ( n = 9), Screener and Opioid Assessment for Patients with Pain (SOAPP; n = 3), SOAPP-Revised ( n = 2), and SOAPP-Short Form ( n = 5). Only two studies’ primary objectives were to evaluate a questionnaire’s psychometric properties in patients receiving palliative care. There was wide variation in how urine drug tests were incorporated into palliative care; frequency of abnormal urine drug test results ranged from 8.6% to 70%. Conclusion: Given the dearth of studies using tools developed or validated specifically for patients receiving palliative care, further research is needed to inform clinical practice and policy regarding problematic opioid use in palliative care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Assessment tools for problematic opioid use in palliative care: A scoping review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Opioid addiction rates have been reported from 0 to 7.7% in cancer patients, however, these studies include data collected prior to the current opioid crisis (Hojsted and Sjogren, 2007b). Prior studies on opioid misuse risk in gynecologic oncology population have shown that up to 29% of patients screen into moderate to high-risk categories for potential opioid misuse (Koyyalagunta et al, 2013), and cervical cancer patients may be at higher risk than those with other gynecologic malignancies (Garcia et al, 2017). In our cohort, risk of opioid misuse was not assessed, and the rate of opioid use disorder was low at 2.3%.…”

Section: Discussionmentioning

confidence: 99%

Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer

Rubinsak

Terplan

Martin

et al. 2019

Gynecologic Oncology Reports

View full text Add to dashboard Cite

The purpose of this study was to identify the prevalence of substance use disorder and its association with adherence to treatment and survival in locally advanced cervical cancer patients treated with primary radiation therapy. This is a retrospective case series of locally advanced cervical cancer patients with substance use disorder in a single academic institution treated with radiation therapy between 2005 and 2016. Substance use disorder was identified through chart review. Those with substance use disorder were compared to those without in regards to demographics, Charlson comorbidity index, treatment details and outcomes. Of the 129 patients with locally advanced cervical cancer, 16 (12.4%) were identified as having substance use disorder. Patients with substance use disorder were younger (42.1 years vs 51.5 years, p = .013) and more likely to be smokers (81.3% vs 42.5%, p = .004). The majority of patients with substance use disorder received concurrent chemotherapy (93.8%) and brachytherapy in addition to external beam radiation therapy (81.3%). There was no significant difference in days to completion of radiation therapy between patients with and without substance use disorder. Radiation dose received, toxicities and survival were similar between groups. Among cervical cancer patients receiving treatment with radiation therapy, substance use disorder was not associated with poorer adherence, longer radiation treatment times or a difference in total dose of radiation received. Our experience demonstrates that patients with substance use disorder are able to adhere to complex, multimodal treatment plans resulting in similar cancer specific outcomes compared to patients without substance use disorder.

show abstract

National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Prescription opioids are frequently prescribed to treat cancer-related pain. However, limited information exists regarding rates of prescription opioid use and misuse in populations with cancer. OBJECTIVES To estimate the prevalence and likelihood of prescription opioid use and misuse in adult cancer survivors compared with respondents without cancer and to identify characteristics associated with prescription opioid use and misuse in adult cancer survivors. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study is a retrospective, populationbased study using data from 169 162 respondents to the National Survey on Drug Use and Health from January 2015 to December 2018. Survey data sets were queried for all respondents aged 18 years or older. Those with a reported history of cancer were termed cancer survivors and further divided into more recent (had cancer within 12 months of survey) and less recent (had cancer more than 12 months prior to survey) cohorts. Respondents with nonmelanoma skin cancer were excluded. MAIN OUTCOMES AND MEASURES Prescription opioid use and misuse within the past 12 months. RESULTS Among 169 162 respondents, 5139 (5.2%) were cancer survivors, with 1243 (1.2%) and 3896 (4.0%) reporting having more recent and less recent cancer histories, respectively. Higher rates of prescription opioid use were observed among more recent cancer survivors (54.3%; 95% CI,

show abstract

Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse

Cited by 17 publications

References 16 publications

Assessment tools for problematic opioid use in palliative care: A scoping review

Assessment tools for problematic opioid use in palliative care: A scoping review

Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer

National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States

Contact Info

Product

Resources

About